Spotlight imatinib: a model for signal transduction inhibitors

被引：9

作者：

Hochhaus, A

McCubrey, JA

Killmann, NMB

机构：

[1] Guest Editor,

[2] Imatinib Spotlight,undefined

[3] Section Editor,undefined

[4] Signal Transduction and Cytokines and Signal Transduction Inhibition,undefined

[5] Advisory Editor,undefined

[6] Section Editor of ‘Molecular Targets for Therapy’,undefined

来源：

LEUKEMIA | 2002年 / 16卷 / 07期

关键词：

D O I：

10.1038/sj.leu.2402575

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1205 / 1206

页数：2

共 18 条

[1] Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8 [J].

Andersen, MK ;

Pedersen-Bjorgaard, J ;

Kjeldsen, L ;

Dufva, IH ;

Brondum-Nielsen, K .

LEUKEMIA, 2002, 16 (07) :1390-1393

[2]

Barthe C, 2001, SCIENCE, V293

[3] Tyrosine kinase fusion genes in chronic myeloproliferative diseases [J].

Cross, NCP ;

Reiter, A .

LEUKEMIA, 2002, 16 (07) :1207-1212

[4]

Druker B.J, 2002, P AN M AM SOC CLIN, V21, P1

[5] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].

Druker, BJ ;

Sawyers, CL ;

Kantarjian, H ;

Resta, DJ ;

Reese, SF ;

Ford, JM ;

Capdeville, R ;

Talpaz, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042

[6] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].

Druker, BJ ;

Talpaz, M ;

Resta, DJ ;

Peng, B ;

Buchdunger, E ;

Ford, JM ;

Lydon, NB ;

Kantarjian, H ;

Capdeville, R ;

Ohno-Jones, S ;

Sawyers, CL .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037

[7] Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT) [J].

Fischer, T ;

Reifenrath, C ;

Hess, GR ;

Corsetti, MT ;

Kreil, S ;

Beck, J ;

Meinhardt, P ;

Beltrami, G ;

Schuch, B ;

Gschaidmeier, H ;

Hehlmann, R ;

Hochhaus, A ;

Carella, A ;

Huber, C .

LEUKEMIA, 2002, 16 (07) :1220-1228

[8] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].

Gorre, ME ;

Mohammed, M ;

Ellwood, K ;

Hsu, N ;

Paquette, R ;

Rao, PN ;

Sawyers, CL .

SCIENCE, 2001, 293 (5531) :876-880

[9]

Hochhaus A, 2001, SCIENCE, V293, P2163

[10] Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation [J].

Hofmann, WK ;

Jones, LC ;

Lemp, NA ;

de Vos, S ;

Gschaidmeier, H ;

Hoelzer, D ;

Ottmann, OG ;

Koeffler, HP .

BLOOD, 2002, 99 (05) :1860-1862

← 1 2 →